You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR ONC201

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for ONC201

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02038699 ↗	A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer	Withdrawn	Chimerix	Phase 1/Phase 2	ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer. This trial includes a phase I portion that will evaluate the safety of ONC201 and the recommended dose for the phase II portion. The phase II portion will evaluate the initial efficacy profile of ONC201 in select types of cancer.
NCT02038699 ↗	A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer	Withdrawn	Oncoceutics, Inc.	Phase 1/Phase 2	ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer. This trial includes a phase I portion that will evaluate the safety of ONC201 and the recommended dose for the phase II portion. The phase II portion will evaluate the initial efficacy profile of ONC201 in select types of cancer.
NCT02250781 ↗	Oral ONC201 in Treating Patients With Advanced Solid Tumors	Completed	National Cancer Institute (NCI)	Phase 1	This phase I trial studies the side effects and best dose of Oral ONC201 in treating patients with advanced solid tumors. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02250781 ↗	Oral ONC201 in Treating Patients With Advanced Solid Tumors	Completed	Rutgers Cancer Institute of New Jersey	Phase 1	This phase I trial studies the side effects and best dose of Oral ONC201 in treating patients with advanced solid tumors. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for ONC201

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Multiple Myeloma	3
Endometrial Cancer	3
Glioblastoma	3
Diffuse Intrinsic Pontine Glioma	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Glioma	7
Glioblastoma	5
Endometrial Neoplasms	4
Colorectal Neoplasms	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ONC201

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	47
France	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	6
Pennsylvania	5
Michigan	4
New York	4
Texas	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ONC201

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	10
Phase 1/Phase 2	6
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	8
Not yet recruiting	5
Active, not recruiting	4
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ONC201

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Oncoceutics, Inc.	15
Chimerix	11
National Cancer Institute (NCI)	7
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Other	31
Industry	28
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.